1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.

LHFI

The share issues has resulted in a change of the registered share capital and shares and votes in Xbrane. As of 31 July 2025, the total number of shares and votes in the Company amounts to 2,549,678,555. The Company's registered share capital amounts to approximately SEK 571,602,393.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 21:00 CEST.

Attachments

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.

Datum 2025-07-31, kl 21:00
Källa MFN
Bifogade filer
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!